Conor Medsystems: Two-year data show CoStar Cobalt stent safety

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Conor Medsystems, Inc. announced two-year follow-up clinical data from the first arm of its pivotal EuroSTAR study of single- and multi-vessel coronary artery disease.

There were low rates of clinical events through 24 months, demonstrating the stability of outcomes with the CoStar stent, officials of the Menlo Park, Calif., drug technology company noted.

In addition, the use of bioresorbable polymers ensures that no permanent polymer residue or drug remains at the target site, which may confer a long-term advantage with respect to reduced rates of late stent thrombosis.

A total of 176 lesions were treated in 145 patients using the CoStar stent formulated to release a therapeutic dose of 10 mcg of paclitaxel per 17 mm stent over about 30 days (based on in vitro measurements).

At 24-month follow-up, the target lesion revascularization rate was 3.6%, compared with 2.8% at 12-month follow-up, and the cumulative major adverse cardiac event rate was 10.4%, compared with 8.3% at 12-month follow-up.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.